We remain on track for phase 2b and phase 3 topline data in non-metastatic, localized prostate cancer for CAN-2409 in the fourth quarter ...

Samtec, Inc. is announcing the availability of full production quantity for its LL043 Series Nitrowave high-performance ...

Samtec, Inc. is announcing the availability of full production quantity for its LL043 Series Nitrowave high-performance ...

As of September 30, Seres Therapeutics (MCRB) had $66.8M in cash and cash equivalents. The company expects to fund operations into Q4 of 2025.